Chief Executive Officer
Tim has 30 years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, commercial operations, strategic planning and business development. Most recently Tim was Chief Business Officer at Aprecia Pharmaceuticals, the leader in 3-D printing of pharmaceutical drug product. Prior, Tim helped build Takeda Pharmaceuticals, starting with the company in 1999. He took on increasing roles of responsibility including leading the US Sales & Managed Markets, Marketing, and BD teams. Tim spent 12 years prior with Parke-Davis Pharmaceuticals.
Chief Medical Officer
Dr. Charlie Baum, MD, MS, FACG
Dr. Baum is a board-certified Gastroenterologist and was most recently Vice President of US and EU Medical and Scientific Affairs at Takeda Pharmaceuticals International. He has extensive experience in the research and development of therapeutics for GI disease, health economics and outcomes research.
Chief Product Officer
Danny Bernstein, Founder
PriortofoundingmetaMe,Dan founded the medication adherence company Medic8 Manager. Dan has training in architecture and experience in computer game design, including projects at Activision and DisneyInteractive. Dan has been living with IBD-Crohn’s and IBS since his early teens.
Chief Financial Officer
Michael received an accounting degree from Michigan State University and a Master of Science in Taxation from the Wayne State University School of Business. After years at Grant Thornton (the world's sixth largest network of accounting firms), and working directly with a public company, Michael left the corporate world to follow his entrepreneurial ambitions. Michael has been with metaMe since 2016.
Chief Technology Officer
Adam is the designer and architect of the metaMe Connect Digital Health platform. He has worked in a variety of languages and environments, including full stack development using Django and Laravel, specializing in backend development. He has extensive experience provisioning cloud infrastructure and continuous integration. He has launched multiple production products.
metaMe Health has assembled leaders in the field of GI health to advise us on scientific, clinical and business matters surrounding digital therapeutics, IBS and Brain-Gut Therapy.
Dr. John Pandolfino, MD
Dr. Pandolfino is the Chief of Gastroenterology and Hepatology in the Department of Medicine at Northwestern Medicine. He is also the Hans Popper Professor of Medicine. A major aim of Dr. Pandolfino’s current research focuses on improving diagnosis and management of GERD patients not responding to proton pump inhibitor (PPI) therapy. This group of patients represents a significant burden as up to 30-50% of all GERD patients are not satisfied with their response to PPI therapy. Additional information about Dr. Pandolfino can be found here.
Dr. Laurie Keefer, PhD
Dr. Keefer is a GI Health Psychologist and the Director of Psychobehavioral Research at the Ichan School of Medicine at Mount Sinai in New York City. She has been a pioneer in the development of effective behavioral therapies for the full range of gastrointestinal disorders, including IBS, Crohn’s Disease, ulcerative colitis, reflux disease and other esophageal disorders. Previously, she was Associate Professor at the Northwestern University Feinberg School of Medicine in Chicago, where she retains an Adjunct appointment. She is licensed in both Illinois and New York.
Nandini Murthy, MS, RAC.
Nandini Murthy guided the first ever digital therapeutic reSET through FDA clearance for PEAR Therapeutics in 2017. Ms. Murthy has over 20 years of work experience in regulatory affairs, clinical and quality assurance functions with multiple device specialties. Having served on the Executive team of several companies, she combines a strategic, solution-oriented mindset with strong tactical instincts.
Dr. Lin Chang, MD
Dr. Chang is Vice-Chief of the Division of Digestive Diseases, Program Director of the UCLA GI Fellowship Program, and Co-Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience (CNSR) and a Professor of Medicine at the David Geffen School of Medicine at UCLA.
Dr. Chang’s clinical expertise is in functional gastrointestinal disorders which include irritable bowel syndrome (IBS), chronic constipation and functional dyspepsia. Her research is focused on the pathophysiology of IBS related to stress, sex differences, genetic and epigenetic factors, neuroendocrine alterations, and gut microbiome and the treatment of IBS. You can learn more about Dr. Chang here.
Dr. Olafur Palsson, PsyD
Dr. Palsson is a clinical psychologist and health researcher with a long-standing interest in the relationship between mind and body in the determination of health and illness. He is originally from Iceland. Dr. Palsson's current research interests include investigation of the psychological and physiological aspects of gastrointestinal disorders and symptoms, development of questionnaires to improve GI research, and the use of psychological treatments for IBS and other functional GI disorders.